MedTrace Logo

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

NCT06125080 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-11-09

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).

Conditions

  • TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Utidelone

Utidelone (30 mg/m2, days 1-5, every 3 weeks)

DRUG

Tirelizumab

Tirelizumab（200mg, day1, every 3 weeks）

DRUG

Bevacizumab

Bevacizumab(7.5mg/kg, day1, every 3 weeks)

Sponsors & Collaborators

  • Huihua Xiong

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2025-10-30
Completion
2026-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06125080 on ClinicalTrials.gov